PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is a major challenge to targeted therapy for non-small cell lung cancer (NSCLC). We investigated whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse EGFR-TKI resistance in human lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Minghui, Xu, Song, Wang, Yuli, Li, Ying, Li, Yongwen, Zhang, Hongbing, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356711/
https://www.ncbi.nlm.nih.gov/pubmed/27825114
http://dx.doi.org/10.18632/oncotarget.13069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356711/
https://www.ncbi.nlm.nih.gov/pubmed/27825114
http://dx.doi.org/10.18632/oncotarget.13069

Ejemplares similares